Effect of bestatin on the establishment of delayed-type hypersensitivity (DTH) to sheep red blood cells (SRBC) and oxazolone was examined in normal and immunity-impaired mice. Administration of a low dose of bestatin (0.1 ti 100 dug/mouse) augmented DTH to SRBC and restored their impaired DTH to oxazolone. The effect of bestatin in the mouse was agedependent. Bestatin retarded the growth of slow growing solid tumors of GARDNER lymphosarcoma and IMC carcinoma and the effect was influenced by the time of the administration and the number of cells inoculated. Bestatin enhanced the antitumor action of the antitumor antibiotics, bleomycin and adriamycin. Bestatin also retarded the induction of skin cancer by 20-methylcholanthrene.
Antitumor antibiotics Both bleomycin ("Bleo", Nippon Kayaku Co., Ltd., Tokyo, Japan) and adriamycin (Kyowa Hakko Co., Ltd., Tokyo, Japan) were dissolved in saline and 0.25 ml of their solutions was injected intraperitoneally.
Murine transplantable tumors IMC carcinoma, GARDNER'S lymphosarcoma and L-1210 were used as syngeneic tumors and EHRLICH carcinoma was used as an allogeneic tumor. These tumors had been transferred at 7-day intervals in each mouse strain.
In 1975, a spontaneously-induced ascitic tumor was found in pooled CDFI mouse (female, 15 weeks old). This tumor can be transferred only through CDFI mice in the ascitic form. Pathological and morphological properties of this tumor have been studied by Dr. EGASHIRA in NIH, Japan and this tumor was named IMC carcinoma. To CDFI mice (female, 11 weeks old), 108 or 5 x 101 IMC cracinoma cells were subcutaneously inoculated to the inguinal area and after the inoculation the size of each tumor was daily measured. As shown in Fig. 1 , there was a lag time of about 10 days and thereafter the tumor continue to grow at the almost constant rate up to 5 -6 weeks. Mice died within 61.4±3.3 or 48.8±3.9 days after the inoculation of 1 x 101 or 5 x 101 cells respectively. This tumor was chosen for the test of antitumor activity of bestatin. Ascitic tumor cells collected 5 days after the intraperitoneal inoculation were washed with saline or DULBECCO'S PBS and the cell suspension containing an adequate number of cells was prepared. The tumor Days after inoculation of IMC carcinoma cells * Mean survival days cells in 0.25 ml were injected subcutaneously to groin of CDF1 mouse. GARDNER'S lymphosarcoma (6C3HED-OG) was maintained by intraperitoneal inoculation of ascitic cells to C3H/He mice. For experiment, ascitic tumor cells of from 5 to 7 days after the inoculation were collected, washed, and suspended at 4 x 106 cells/ml in saline, and 105 cells were inoculated subcutaneously at groin of each C3H/He mouse to produce a solid tumor.
Ascitic lymphoid leukemia L-1210 was maintained in CDF1 mice, and 105 cells were intraperitoneally injected in experiments where the antitunzor effect of bestatin was tested in combination with adriamycin.
EHRLtcH ascites tumor was maintained in female out bred ICR or dd Y mice. In experiment where the effect on footpad tumors was tested, ascitic tumor cells of from 5 to 7 days after the intraperitoneal inoculation of tumor cells were washed with saline thoroughly and suspended in saline at 2 x 101 cells/ml. The tumor cell suspension (0.05 nil) was inoculated to the footpad of left hind paw subcutaneously. In order to test the effect on secondary tumors 7 days after the first inoculation, the same number of tumor cells were inoculated to the footpad of the other hind paw. The tumor size in 0.1 mm was recorded by measuring the thickness of footpad by a caliper. In the experiment testing the effect on the ascites tumor, I or 2 x 106 cells in 0.25 ml were intraperitoneally injected to ddYor ICR mice.
Induction of skin cancer in mice by 20-methylcholanthrene Mice (ddY, female, 11 weeks old) were shaved at back near neck every week and two drops of saturated 20-methylcholanthrene (20-MC, Eastman Organic Chemicals, Rechester, N. Y., U.S.A.) in acetone was painted twice a week for 10 weeks. Each mouse was weighed every week and the induction of cancer was checked. 20-Methylcholanthrene-induced skin tumors were confirmed to be squamous cell carcinoma by pathological examination. Mice were given 10 ug of bestatin orally on various days before or after the immunization with SRBC and their DTH response to SRBC was tested. Oral administration of bestatin 1-6 days before immunization and 0, 1, 2, 3 days after immunization was effective in enhancing DTH. Bestatin was most effective when given a day before and 0-3 days after immunization. The best timing of bestatin Table 3 . Effect of bestatin on DTH response to SRBC in mice immunized by intravenous injection of SRBC. administration to enhance DTH appeared to be the day of immunization or I day thereafter. The effect of consecutive administration of bestatin was examined on DTH response. Mice (ddY. female, 8 weeks old) were immunized and were given 1 pg of bestatin orally on day 1 or days 1, 2 or days 1, 2 and 3 after immunization. A single administration of bestatin at day I was the most effective regimen.
Bestatin administration initiated 2 days after the immunization was least effective. As reported previously6), the administration of bestatin at the time of the eliciting injection of SRBC was not effective. The effect of bestatin in enhancing DTH produced by intravenous injection of 105, SRBC was tested. CDF1 mice (female, 10 weeks old) were immunized by intravenous injection of 105 SRBC and were given different doses of bestatin orally.
Four days later, 101 SRBC were subcutaneously injected to footpad of left hind paw and after 24 hours, the thickness of resulting edema in each mouse was measured. As shown in Table 3 , the lower doses of bestatin (0.1, 1 or 10 ug/mouse) were markedly effective in augmenting DTH response. The optimal dose was 10 ug/mouse. High doses of bestatin, 100 or 1,000 Erg/mouse did not show a significant effect. given once orally at the time of the immunization. Mice were sensitized by painting 0.1 nil of 5 % oxazolone in ethanol and 2 days or 4 days thereafter, bestatin given orally. The same volume of oxazolone was painted to footpad.
The resulting edema was measured 24, 48 and 72 hours after the second oxazolone painting. Different doses of bestatin were given orally at the same time. Five days later, mice were challenged by injection of SRBC to the other footpad and the thickness of resulting edema was measured.
As shown in Table 5 , compare to normal mice, DTH response was markedly impaired in tumorbearing mice. Bestatin in low doses (10 or 1 ug/mouse) restored the reduced DTH response by 78 or 56 %. Higher doses of bestatin, 100 or 1,000 ug/mouse, did not restore the reduced DTH.
Effect of Bestatin on Delayed-Cutaneous Hypersensitivity to Oxazolone Effects of bestatin on DCH to oxazolone in non-treated mice and in immunity-impaired mice were studied.
Mice (CDF1, female, 11-12 weeks old) were sensitized by painting 0.1 ml of 5 % oxazolone on the shaved abdomen. Bestatin (1, 10, 100 or 1,000 ug/mouse) was given orally. Two or four days later, oxazolone solution was painted on the footpad of hind paw to elicite the reaction, and 24, 48 and 72 hours later the resulting edema was measured. As shown in Table 6 , when the second oxazolone solution was painted 2 days after the sensitization, the maximal response was observed at 48 hours and when the second oxazolone solution was painted 4 days after the sensitization the maximal response was observed at 24 hours thereafter. This assay method was employed to test the effect of bestatin on DCH to oxazolone in following experiments.
To CDF1 mice 6 mg of cyclophosphamide was injected intravenously and bestatin (10 Table 7 , the administration of 100 ug/mouse/day bestatin for 5 days before the inoculation and the administration of 1, 10 or 100 ug/mouse/day bestatin started from one day after the inoculation was somewhat effective in suppressing the growth of the tumor, but the effect was fluctuated in each mouse. The administration of bestatin started on day 8 for 14 days after the inoculation suppressed the growth of the tumor. As shown in Table 7 , there was no dose-dependency, although 10 or 100 jig/mouse/day orally seemed to be the optimal dose to suppress the growth of this tumor. The administration of a high dose such as 1,000 ug/mouse/days was not effective. As shown in Fig. 2 , the treatment of 10 jig/mouse bestatin on day 8 after the inoculation of tumor cells showed the greatest effect. The effect of bestatin was tested on a subcutaneous solid tumor of GARDNER'S lymphosarcoma.
Mice (C3H/He, female, 8 weeks old) were implanted 105 ascitic GARDNER'S lymphosarcoma cells to groin subcutaneously and 10 or 100 ug/mouse oral bestatin was given daily for 5 days from one day to 5 days after the implantation of tumor cells. Thirty days later, tumors were extirpated and weighed.
As shown in Table 8 , 10 or 100 u-g/mouse/day inhibited the tumor growth by 60~78 %.
The effect of bestatin in combination with bleomycin or adriamycin was studied. When 108
EHRLICH ascites tumor cells were inoculated to footpad of hind paw of ddY mice subcutaneously, the maximal tumor growth was observed in 2 -3 weeks after the inoculation without spontaneous regression.
Bleomycin and other antitumor substances which are known to be effective against ascites and solid forms of EHRLICH carcinoma were ineffective in the footpad tumor. In an experiment 108 EHRLICH carcinoma cells were inoculated to hind footpad, from day 1, 100 ug of bleomycin, 1, 10, 100 or 1,000 ug/mouse of bestatin alone or both of them were given daily intraperitoneally for 6 successive days. Thirty days after the implantation, the size of each tumor was recorded in 0.1 mm. As shown in Table 9 , although 100 jig of bleomycin or each dose of bestatin alone was ineffective in suppressing the tumor, the In this allogeneic system, the effect of bestatin in rejecting the secondary tumor was studied. As indicated in Table 10 , 106 EHRLICH carcinoma cells were inoculated to footpad of right hind paw to produce the primary tumor. Bleomycin alone, bestatin alone or bleomycin with bestatin was given daily for 6 days starting day I after the transplantation of tumor cells, and 7 days after the inoculation of tumor cells 108 tumor cells were inoculated to the other hind footpad to produce the secondary tumor. Fourteen days after the inoculation the size of each primary and secondary tumor in footpad was measured.
As shown in Table 10 , although the treatment with bleomycin or bestatin alone inhibited growth of the secondary tumor by 42 % or 59 % respectively, the treatment of bleomycin (100 jig/mouse) with bestatin type hypersensitivity to SRBC in a wide dose range. The optimal dose for enhancing DTH to SRBC was in the range of 1~100 , sg/mouse. In order to see the effect of bestatin in enhancing DTH, it was necessary to test it on aged mice, that is, those older than 8 or 10 weeks. Bestatin augmented DTH when it was administered intraperitoneally, intravenously and orally. The administration through subcutaneous route was not useful in evaluating the effect of bestatin. It has been reported that in the delayed-cutaneous hypersensitivity to oxazolone in mice, T cell/macrophage mediated events are involved in early response, and B cells in late response10). HEM SWORTH et al.11) reported that tumorassociated or drug-induced anergy to oxazolone was a suitable model for evaluation of the activity of compounds. We studied the optimal condition in testing bestatin effect on DCH to oxazolone: the method which the thickness of edema is measured 48 hours after the oxazolone painting to elicite the reaction appears to give the best result. We examined the effect of bestatin on the early DCH response to oxazolone in mice which were treated with cyclophosphamide or inoculated with EHRLICH ascites tumor. Administration of bestatin before the sensitization restored the anergy induced by injection of cyclophosphamide. Bestatin also restored the reduced DCH to oxazolone response in EHRLICH ascites tumor-bearing mice to that of tumor-free mice. Bestatin showed a strong action in restoring the reduced DCH to oxazolone. These effects of bestatin on delayed-type hypersensitivity to SRBC and to oxazolone indicate that bestatin enhances the establishment of cell-mediated immune responses and restores the reduced functions of cell-mediated immune reactions. Mechanisms of action of bestatin in enhancing immune responses have been studied by testing the mitogenic action of bestatin on murine splenic lymphocytes, and as will be reported in the following papers12), it has been suggested that bestatin causes the proliferation of T cells through the activation of macrophages.
Antitumor effect of bestatin was examined on syngeneic or allogeneic murine tumors. Bestatin was ineffective in suppressing EHRLICH ascites tumor or L-1210. Against the solid form of IMC carcinoma, as syngeneic tumor, oral administration of bestatin retarded the growth of the tumor, when bestatin treatment was started 8 or 14 days after the inoculation of tumor cells. The tumor growth after the inoculation of smaller number of tumor cells was more susceptible to bestatin treatment than a large number of cells such as 107. Since mice die about 40 to 60 days after the inoculation of 1 or 5 x 10° cells/mouse of IMC carcinoma, IMC carcinoma seems to be a slowly growing tumor in which defense mechanisms are somewhat preserved. The antitumor activity of bestatin on this tumor may depend on the stimulation of the defense mechanisms.
Against fast growing tumors such as EHRLICH carcinoma and L-1210, bestatin enhanced the therapeutic effect of adriamycin and bleomycin. The mechanism of this synergistic effect may be explained as follows. The destruction of cancer cells by antitumor substances may decrease the release of immunosuppressive products from cancer cells and bestatin may enhance the defense mechanism or destroy cells which may produce antigens free from cells.
Bestatin retarded the induction of skin cancer by 20-MC. Small molecular weight immunomodulators such as bestatin may be useful in analysis of immune mechanisms in cancer patients.
